Pain affects everyone at some time in their life, be it chronic arthritis or a one-off injury.
13th February 2019
11th February 2019
Medherant has been included in the Silicone Republic Europe Start-up 100 for 2019 which looks at the companies to watch this year in e-commerce and fintech, deeptech, hardware and IoT, and medtech and life sciences.
21st January 2019
Last year was another busy year for Medherant with a significant milestone reached when we received positive results from the first clinical trials with our TEPI Patch® technology.
5th November 2018
Medherant, a developer of innovative transdermal drug delivery treatments for pain and CNS diseases, has successfully completed two Phase I studies with its novel Ibuprofen TEPI Patch®.
3rd October 2018
Medherant, a developer of innovative transdermal drug delivery treatments for pain and CNS diseases, has been awarded a Medicines Manufacturing Grant by Innovate UK.
11th September 2018
Medherant has been shortlisted for the CPhI Pharma Awards in both the Formulation and Drug Delivery Devices categories for its TEPI Patch® technology.
6th June 2018
Transdermal drug delivery systems have been used in different forms since ancient times.
14th February 2018
There are many problems linked to oral drug administration including first pass metabolism, gastrointestinal tract damage and low levels of drug reaching the target site.
18th December 2017
The Journal of Pharmaceutical Innovation, Springer, has published the research paper 'Transdermal Delivery of Ibuprofen Utilizing a Novel Solvent-Free Pressure-sensitive Adhesive (PSA): TEPI® Technology'
11th December 2017
Medherant, a leader in next-generation transdermal drug delivery, has raised £3.8 million in its latest funding round. The fundraising was led by majority shareholder Mercia Technologies PLC, with the balance coming from other existing shareholders as well as new private investors. This latest investment will support the company as it progresses its ibuprofen TEPI Patch® into clinical development in early 2018.